Aberdeen Group plc Reduces Stock Position in Immatics N.V. $IMTX

Aberdeen Group plc trimmed its position in Immatics N.V. (NASDAQ:IMTX) by 9.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 714,569 shares of the company’s stock after selling 74,877 shares during the quarter. Aberdeen Group plc owned 0.59% of Immatics worth $7,503,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Bank of America Corp DE increased its position in Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after buying an additional 2,231 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its holdings in shares of Immatics by 8.3% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 47,635 shares of the company’s stock valued at $406,000 after purchasing an additional 3,666 shares during the period. Insigneo Advisory Services LLC acquired a new position in shares of Immatics in the third quarter valued at about $103,000. Engineers Gate Manager LP acquired a new stake in Immatics during the second quarter worth about $124,000. Finally, BNP Paribas Financial Markets grew its holdings in Immatics by 105.2% during the second quarter. BNP Paribas Financial Markets now owns 78,123 shares of the company’s stock worth $420,000 after acquiring an additional 40,058 shares during the period. 64.41% of the stock is currently owned by hedge funds and other institutional investors.

Immatics Trading Up 2.7%

NASDAQ:IMTX opened at $10.53 on Thursday. The stock has a fifty day simple moving average of $9.88 and a 200-day simple moving average of $9.85. Immatics N.V. has a twelve month low of $3.45 and a twelve month high of $12.41. The company has a market cap of $1.41 billion, a price-to-earnings ratio of -5.72 and a beta of 1.34.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.14. Immatics had a negative return on equity of 41.81% and a negative net margin of 411.90%.The business had revenue of $23.00 million for the quarter, compared to analyst estimates of $12.18 million. As a group, equities research analysts predict that Immatics N.V. will post -0.72 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Wall Street Zen upgraded Immatics from a “sell” rating to a “hold” rating in a research report on Monday, March 9th. Mizuho set a $25.00 target price on Immatics in a research report on Thursday, February 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immatics in a report on Thursday, January 22nd. Finally, Jefferies Financial Group started coverage on Immatics in a report on Monday, March 16th. They issued a “buy” rating and a $18.00 price target for the company. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $19.00.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.